Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Washington Threatens; Wall Street Reacts

This article was originally published in RPM Report

Executive Summary

The biotech investment boom hit the brakes at the end of the first quarter when Rep. Henry Waxman (D-Calif.) publicly complained about Gilead’s pricing for the hepatitis C therapy Sovaldi. The fact that Waxman’s attack has little substantive impact didn’t seem to matter. Another Washington threat—to undo “tax inversion” strategies—is probably much more real, but may actually boost the sector for the rest of 2014.


Related Content

A New Type of Investor Relations for Biopharma
A New Type of Investor Relations for Biopharma
Congressional Dems Generating Heat, But No Hearings, On Rx Prices
The Campaign Against Drug Pricing: Candidates Can Only Hope Voters React As Strongly As Wall Street
When Empty Threats Work: “Price Negotiation” In White House Budget Spooks Wall Street
Gilead’s Sovaldi: Shooting Star Instead of Blockbuster
Biotech Investors Howling At Yellen After Federal Reserve Report Roils Sector
Covering Breakthroughs: Payors in New Territory
The Zaltrap Price Debate: Less Than Meets The Eye
Ending “Buy-And-Bill” in Oncology: The Question is How, Not If


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts